SOUTH SAN FRANCISCO, Calif., May 12 NapoPharmaceuticals, Inc., (LSE: NAPL and NAPU), announces that it presented aposter in collaboration with QualityMetric, Inc. describing the development ofa patient reported outcomes questionnaire focused on the Health-RelatedQuality of Life (HR-QoL) aspects of chronic diarrhea in persons living withHIV/AIDS at the 13th International Society for Pharmacoeconomics and OutcomesResearch (ISPOR) Annual Meeting in Toronto, Ontario, May 3 through 7, 2008.
Using classic and modern psychometric methods, a single scale comprised of9 survey questions covering two HR-QoL content areas was developed. The surveyquestions showed consistency across gender, race and education level,demonstrated a statistically significant greater negative impact on HR-QoLwith more frequent and more severe diarrhea symptoms.
Cathy Olufs, President, AIDS Activist Treatment Coalition (ATAC) stated,"We are fortunate to currently have a wide choice of HIV medications andcombinations. This makes understanding medication side effects and theirimpact on a patient's quality of life more important than ever. Controllingside effects such as diarrhea can help give patients access to the fullarmamentarium of anti-retroviral drugs. We are pleased to see Napo taking theinitiative to develop this new instrument to measure health-related quality oflife as affected by diarrhea."
About Napo Pharmaceuticals, Inc.
Napo Pharmaceuticals, Inc. focuses on the development andcommercialization of proprietary pharmaceuticals for the global marketplace incollaboration with local partners. Napo was founded in November 2001, and isbased in California, USA with a subsidiary in Mumbai, India.
Napo's late-stage proprietary gastro-intestinal compound, crofelemer, isin various stages of clinical development for four distinct productindications, including a late-stage Phase 3 program:
The FDA has granted fast-track status to CRO-IBS and CRO-HIV.
Crofelemer, a proprietary patented agent, is extracted from Crotonlechleri, a medicinal plant which can be sustainably harvested from severalcountries in South America. Napo also plans to develop an early clinical stageproduct, NP-500, for the treatment of insulin resistant diseases of Type IIdiabetes and metabolic syndrome (Syndrome X; pre-diabetic syndrome). Napo alsohas a plant library of approximately 2,300 medicinal plants from tropicalregions, and Napo has entered two screening relationship associated with thiscollection.
Currently, products are based on the chemical and biological diversityderived from plants with medicinal properties, but future products may bein-licensed from other sources.
Napo has partnerships with Glenmark Pharmaceuticals Limited of India andAsiaPharm Group Ltd. of China.
For more information please visit www.napopharma.com.
ISPOR promotes the science of pharmacoeconomics (health economics) andoutcomes research (the scientific discipline that evaluates the effect ofhealth care interventions on patient well-being including clinical outcomes,economic outcomes, and patient-reported outcomes) and facilitates thetranslation of this research into useful information for healthcaredecision-makers to ensure that society allocates scarce health care resourceswisely, fairly and efficiently.For more information please contract: Napo Pharmaceuticals, Inc. Lisa Conte, Chief Executive Officer 1 + 650 616 1902 David Golman, Pharm.D., Senior Director, Clinical Operations 1+ 760 918 5718
SOURCE Napo Pharmaceuticals, Inc.